MPS I Orchard Therapeutics Announces Interim Data for OTL-203 Showing Positive Clinical Results in Multiple Disease Manifestations of Mucopolysaccharidosis Type I Hurler Syndrome (MPS-IH). Read the full report >> SiglionTherapeutics, Development of a Novel...
This will be held on the evening of Saturday, July 22, 2023 in conjunction with the National Family Conference. Head to our National Family Conference page for more details!
